Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase 1 following Successful Thrombectomy in Patients with Large 2 Vessel Occlusion: Study Rationale and Design of A Phase 1/2 3 **Randomized Clinical Trial** 4 5 Xianhua Hou^{1*}, MD, Jiacheng Huang^{2,3*}, MD, Changwei Guo^{2*}, MD, Li 6

- Wang^{4*}, MD, Yuxuan He^{1*}, MD, Lin Chen¹, MD, Qu Liu¹, MD, Junhua 7
- Wu¹, MD, Min Wu¹, MD, Yazhou Wu⁵, PhD, Thanh N. Nguyen⁶, MD, 8
- Raul G. Nogueira⁷, MD, Duolao Wang⁸, PhD, Jeffrey L. Saver⁹, MD, 9
- Wenjie Zi^{2#}, MD, Zhenhua Zhou^{1#}, MD 10
- 11

Institutions 12

- 1.Department of Neurology, Southwest Hospital, Army Medical 13 University, Chongqing, China; 14
- 2. Department of Neurology, Xingiao Hospital, Army Medical University, 15
- Chongqing, China; 16
- 3.Department of Neurology, The Second Affiliated Hospital of 17 Chongqing Medical University, Chongqing, China; 18
- 4.Department of Neurology, Zigong Third People's Hospital, Zigong, 19
- Sichuan, China; 20
- 5.Department of Health Statistics, College of Preventive Medicine, Army 21
- Medical University, Chongqing, China. 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 6.Department of Neurology and Radiology, Boston Medical Center, USA;
- 24 7.UPMC Stroke Institute, Departments of Neurology and Neurosurgery,
- 25 University of Pittsburgh School of Medicine, PA, USA;
- 26 8.Global Health Trials Unit, Liverpool School of Tropical Medicine,
- 27 Liverpool, UK;
- 9.Department of Neurology and Comprehensive Stroke Center, David
- 29 Geffen School of Medicine, University of California, Los Angeles, CA,
- 30 USA.
- 31
- ³² * First co-authors.
- 33 # Co-corresponding authors.
- 34 Total words: 2282
- 35 Number of figures: 1
- 36
- 37 Corresponding authors:
- 38 Zhenhua Zhou, MD
- 39 Department of Neurology, Southwest Hospital, Army Medical University,
- 40 30 Gaotanyan Main St., Shapingba District, Chongqing 400038, China.
- 41 E-mail: <u>exploiter001@126.com</u>.
- 42
- 43 Wenjie Zi, MD
- 44 Department of Neurology, Xinqiao Hospital, Army Medical University,

45 No. 183 Xinqiao Main Street, Shapingba District, Chongqing 400038,

- 46 China
- 47 Email: ziwenjie1981@163.com
- 48

49 Abstract

Background: Adjunct intra-arterial thrombolysis has been shown to potentially improve clinical outcomes in patients with large vessel occlusion (LVO) stroke who have undergone successful endovascular thrombectomy (EVT). Tenecteplase, known for its enhanced fibrin specificity and extended activity duration, may be a better choice than alteplase for intra-arterial thrombolysis. However, the optimal dose, safety and efficacy of intra-arterial tenecteplase remain unclear.

57 **Objective:** To evaluate the optimal dose, safety and efficacy of 58 adjunctive intra-arterial tenecteplase following successful EVT in LVO 59 patients.

Methods and design: This study is a two-part, phase Ib/IIa, multicenter, 60 open-label, 14+8 dose-escalation (Part I) and dose-expansion (Part II) 61 trial conducted in China involving patients LVO patients who achieved 62 successful EVT (defined as the expanded Thrombolysis in Cerebral 63 Infarction [eTICI] grade of 2b50 or higher) within 24 hours of last known 64 well. In Part Ib, the dose escalation will be conducted in up to four tiers 65 of 14+8 patients, starting at 0.03125 mg/kg, to a planned maximum of 66 0.1875mg/kg, and the primary outcome is symptomatic intracranial 67 hemorrhage within 24 hours. In Part IIa, 157 patients will be randomized 68 among two selected safe doses and a placebo, and the primary outcome 69

70	will be the proportion of patients with nondisabled outcome (modified
71	Rankin Scale score of 0 to 1) at 90 days.
72	Discussions: This pivotal trial will provide important data on adjunctive
73	intra-arterial tenecteplase following successful EVT in patients with acute
74	ischemic stroke due to LVO and may support advance of treatment
75	standards.
76	Trial registry number: ChiCTR2300073787 and ChiCTR2400080624
77	(www.chictr.org.cn).
78	Keywords: Clinical trial, Tenecteplase, Mechanical thrombectomy,
79	Acute ischemic stroke, Large vessel occlusion
80	
81	
82	
83	
84	
85	
86	

87 Introduction

Stroke is one of the leading causes of morbidity and mortality 88 worldwide.¹ Endovascular thrombectomy (EVT) is currently 89 recommended as the gold standard treatment for acute ischemic stroke 90 caused by large vessel occlusion (LVO).² However, a meta-analysis study 91 consisted of five randomized clinical trials indicated that two-thirds of 92 patients had disabled (modified Rankin Scale [mRS] 2-6) outcomes after 93 despite successful reperfusion (defined EVT as the extended 94 Thrombolysis In Cerebral Infarction [eTICI] grade of 2b50 or higher.^{3,4} 95 Already infarcted tissue present before the procedure, combined with 96 lacking sufficient infarct expansion into areas macroand 97 microcirculatory reperfusion afterward, may lead to incomplete 98 functional recovery.⁵ Previous studies demonstrated that even when 99 successful reperfusion has been achieved after EVT, hypoperfusion is 100 common and this is associated with poor clinical outcomes.⁶ Preclinical 101 studies have shown that capillary occlusion, perivascular space 102 obstruction, or distal microembolism from a proximal thrombus may 103 cause incomplete reperfusion of the microcirculation and distal 104 vasculature.⁷ 105

Targeting the mirco-thrombi, the Effect of Intra-arterial Alteplase vs
 Placebo Following Successful Thrombectomy on Functional Outcomes in
 Patients With Large Vessel Occlusion Acute Ischemic Stroke (CHOICE)

6 / 24

study showed that adjuvant intra-arterial thrombolysis after successful
reperfusion by EVT could improve excellent functional outcome at 90
days.⁸ However, this study was terminated prematurely with a resulting
limited sample size.

Tenecteplase is a modified form of alteplase, with a longer half-life 113 and greater fibrin specificity.^{9,10} After extensive exploration, preliminary 114 research established the optimal dose of intravenous TNK (0.25 mg/kg) 115 for thrombolysis therapy in stroke.¹¹ In the Tenecteplase versus Alteplase 116 before Thrombectomy for Ischemic Stroke (EXTEND-IA TNK) study, 117 administering tenecteplase (0.25 mg/kg) prior to thrombectomy resulted 118 in a higher rate of reperfusion and improved functional outcomes 119 compared to alteplase (0.9 mg/kg) in patients with LVO stroke.^{10,12} 120 Considering the advantages of tenecteplase, adjuvant intra-arterial 121 administration of tenecteplase may provide greater potential benefits for 122 patients with LVO stroke following successful reperfusion compared with 123 alteplase. However, the optimal dose, efficacy, and safety of intra-arterial 124 tenecteplase following successful reperfusion is unknown. 125

Therefore, we conduct a two-part, phase Ib/IIa, multicenter, open-label, 14+8 dose-escalation (Part 1) and dose-expansion (Part 2) trial to determine the most promising dose to advance to a pivotal trial of intra-arterial tenecteplase following successful thrombectomy in patients with acute ischemic stroke due to LVO within 24h of symptom onset.

7 / 24

131 Methods

132 Study design

The Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase 133 following Successful Thrombectomy in Patients with Large Vessel 134 Occlusion (DATE) is an open-label, randomized, multicenter, Phase Ib/IIa 135 clinical trial designed to identify a dose of intra-arterial tenecteplase 136 following successful EVT in patients with acute ischemic stroke due to 137 LVO that shows sufficient evidence of safety and efficacy to advance to a 138 pivotal trial. In designing this protocol, we adhered to the SPIRIT 139 reporting guidelines¹³ for clarity and consistency. The DATE trial will be 140 divided into two parts: the first part (Phase Ib) is a pilot dose-escalation 141 safety study, and the second part (Phase IIa) is an exploratory study to 142 assess the safety and potential efficacy of adjunctive intra-arterial 143 tenecteplase after successful EVT in patients with LVO stroke at two 144 different doses. After the completion of Phase Ib, a data safety monitoring 145 board (DSMB) unblinded to study groups will select 2 doses (A or B) to 146 be tested in Phase IIa according to the initial safety results. 147

148 **Dose Escalation (Phase Ib)**:

This is a dose escalation trial. During this phase, participants will receive intra-arterial administration of increasing doses of tenecteplase after successful EVT. Patients will be treated with up to 4 escalating dose

levels: 0.03125 mg/kg (1/8 *i.v* dose), 0.0625 mg/kg (1/4 *i.v* dose),0.125
mg/kg (1/2 *i.v* dose), and 0.1875 mg/kg (3/4 *i.v* dose).

According to the Chinese Acute Anterior Circulatory Ischemic 154 Stroke Endovascular Treatment Registry Study, 13.8% of patients 155 experienced symptomatic intracranial hemorrhage (sICH) within 24 hours 156 of receiving EVT.¹⁴ Using sample sizes typical for dose escalation phase I 157 clinical trials^{15,16}, we will use a 14+8 design scheme with sICH 158 occurrence within 24 hours after EVT as the dose-limiting toxicity. At 159 each tier, 14 patients will initially be enrolled. If fewer than 2 of 14 160 subjects develop sICH, the trial will advance to the next tier. If 2 of the 14 161 develop sICH, 8 more patients will be enrolled at that dose. If 0-1 of the 162 additional 8 patients develops sICH, the trial will advance to the next tier. 163 If 2 of the additional 8 patients develops sICH or 3 of the first 14 develop 164 sICH, that dose will be deemed not tolerated and the immediately 165 preceding dose will be the estimated maximum tolerated dose. The chart 166 is shown in Figure 1. 167

168 **Dose Expansion (Phase IIa):**

Two doses (A and B) will be chosen by the DSMB and investigators jointly according to the results in Phase Ib. In Phase II, a total of 157 new patients will be enrolled, with 46 patients assigned to the dose A group, 46 patients assigned to the dose B group, and an additional 65 patients allocated to the control group.

During this phase, 3 arms will be studied and patients will be 174 randomized with stratification allocation according to two strata: patient 175 age (<70 vs \geq 70 years), and admission NIHSS score (< 15 vs \geq 15), to 176 receive 1 of the 2 selected doses of tenecteplase, or to the control group in 177 a 1:1: $\sqrt{2}$ ratio, which in turn yields probabilities of assignment of 0.293, 178 0.293, and 0.414, respectively. Patients will be randomly assigned by 179 using a real-time internet-based system. This process is automated which 180 allows for concealment of the sequence of allocation. 181

Objectives: The primary objective of this study is to preliminarily assess the safety and efficacy of adjunctive intra-arterial tenecteplase at different doses following successful EVT in patients with acute ischemic stroke due to LVO to determine the promising dose to advance to a pivotal trial. Outcome: The study is designed to have two parts with different

- 187 outcomes.
- **188 Dose Escalation (Phase Ib)**

• *Primary outcome:* The primary outcome is sICH within 24 hours.

- 190 Secondary outcome:
- 1) 90-day modified mRS score 0-1 (%);

2) Proportion of patients with functional independence (mRS
score 0 to 2) at 90 days;

194 3) Level of disability (ordinal distribution of mRS scores) at 90
195 days;

196	4) Favorable shift in reperfusion on the eTICI score after
197	intra-arterial tenecteplase thrombolysis therapy. All post-EVT, pre-IA
198	and final post-IA final, angiograms will be scored at a core lab by
199	central and blinded reviewers using the eTICI and classified as
200	eTICI2b, eTICI2c, and eTICI3. The post treatment angiographies will
201	be scored using the eTICI and classified as "improved", "worsened"
202	or "unchanged" with regard to the pre-IA infusion eTICI score.
203	5) The change from baseline of the NIHSS score to 5–7 days or

discharge if earlier;

- 6) EQ-5D-3L at 90 days;
- 206 7) Mortality within 90 days.

207 **Dose Expansion (Phase IIa):**

• *Primary outcome:* The primary outcome will be the proportion of 208 patients with a nondisabled outcome (mRS score of 0 or 1) at 90 (\pm 14) 209 days. Primary outcome assessments will be performed at 90 (\pm 14) days 210 by two independent, certified physicians who are blinded to the treatment 211 details. To maintain the reliability, accessibility, and traceability of the 212 mRS score, we will retain a video or audio records of the 90-day 213 follow-up for all patients. If video or audio recordings are unavailable, 214 outcomes will be determined in-person by certified local investigators, 215 who will be also unaware of the treatment assignment. 216

217

• Secondary outcomes:

1) Proportion of patients with functional independence (mRS score 0
to 2) at 90 days;

220 2) Level of disability (ordinal distribution of mRS scores) at 90 days;

3) Favorable shift in eTICI score after intra-arterial tenecteplase

- 222 thrombolysis therapy;
- 4) The change of the NIHSS score from baseline to 5–7 days or discharge;
- 5) EQ-5D-3L at 90 days;
- 6) sICH rate within 24 hours;
- 227 7) Mortality within 90 days.

228 Inclusion and exclusion criteria

229 Inclusion criteria

1) Age ≥ 18 years;

231 2) Time from last known well within 24 hours;

3) Large vessel occlusive stroke in the anterior circulation confirmed
by computed tomography angiography/magnetic resonance angiography,
including intracranial segment of the internal carotid artery, first or
second segment of the middle cerebral artery;

- 4) Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 based on
 non-contrast computed tomography;
- 5) National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 ;
- 6) Successful endovascular thrombectomy (eTICI 2b-3);

240	7) Total pass numbers of thrombectomy procedure ≤ 3 ;			
241	8) Written informed consent signed by patient or their family			
242	member.			
243	Exclusion criteria			
244	1) NIHSS score ≥ 25 ;			
245	2) Intracranial hemorrhage confirmed by computed tomography or			
246	magnetic resonance imaging;			
247	3) Treated by intravenous thrombolysis;			
248	4) Prestroke mRS score ≥ 2 .			
249	5) Intraprocedural digital subtraction angiography suggests vessel			
250	penetration, dissection, or extravasation of contrast medium;			
251	6) Pregnant or lactating patients;			
252	7) Allergic to contrast agent or Tenecteplase;			
253	8) Systolic pressure greater than 185 mmHg or diastolic pressure			
254	greater than 110 mmHg despite blood pressure lowering treatment;			
255	9) Genetic or acquired bleeding disposition with anticoagulation			
256	factor deficiency or already taking oral anticoagulants within 48 hours			
257	and INR > 1.7;			
258	10) Blood glucose < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400			
259	mg/dl), platelets < 90*10^9/L;			
260	11) History of bleeding in the last 1 month (gastrointestinal and			
261	urinary tract bleeding);			

262 12) Patients on chronic hemodialysis and severe renal insufficiency
263 (glomerular filtration rate < 30 ml/min or blood creatinine > 220 μmol/L
264 [2.5mg/dl]);

13) Any terminal illness with a life expectancy of less than 6months;

14) Intracranial aneurysm, arteriovenous malformation;

15) Brain tumor with occupying mass effect on imaging;

16) Puncture to reperfusion time > 90 min;

270 17) Current participation in another clinical trial;

18) Unlikely to be available for 90-day follow-up.

272 **Participating center eligibility**

To qualify for participation in this trial, study centers will be mandated to have performed a minimum of 50 endovascular procedures each year. Additionally, all neurointerventionists involved will be required to have over five years of experience in cerebrovascular interventions, along with a track record of having performed at least 30 cases of mechanical thrombectomy using stent retriever devices annually.

279 Enrollment

Before initiating any procedure, participants or their legally authorized representatives will be provided with comprehensive oral and written information regarding the study, encompassing its objectives,

potential risks, and anticipated benefits. Subsequently, they will berequired to give their informed consent.

All individuals who fulfill the specified eligibility criteria are eligible for enrollment in the DATE clinical trial.

287 Study Intervention

Eligible patients assigned to the tenecteplase group will undergo an infusion of intra-arterial tenecteplase with the assigned dose. This infusion will be administered through a distal access catheter or microcatheter positioned proximal to the initially occluded artery. Patients allocated to the control group will terminate the procedure without further intraarterial thrombolysis.

All enrolled patients should be monitored in the acute stroke unit and can be admitted to the intensive care unit if necessary. All enrolled patients will undergo standardized medical treatment management and subsequent secondary preventive medication according to the Chinese Guidelines for Endovascular Treatment of Acute ischemic Stroke 2018.¹⁷

299 Blinding and masking

Each participating site will allocate one or more physicians to perform follow-up evaluations at 24-hour intervals, between five to seven days post-treatment, or at the time of discharge if it occurs sooner, along with a 90-day assessment. It is imperative that these physicians are not

involved in the subject's initial treatment to ensure their blinding to thetreatment assignment.

306 Data safety monitoring board

The independent Data and Safety Monitoring Committee (DSMB) is responsible for reviewing the aggregated data and determining the study safety endpoints. The DSMB regularly reviews the study data added during the trial and advises the sponsor on the continued safety of the subjects and those not yet included in the study. The DSMB advises on the continued effectiveness and scientific value of the study.

313 Sample size estimates

314 Dose Escalation (Phase Ib):

The Endovascular Treatment for Acute Anterior Circulation Ischemic Stroke registry in China showed that the incidence of sICH within 24 hours after EVT was 13.8%.¹⁴ Based on this data, we designed a 14+8 enrollment plan as follows:

1) 14 subjects will be included in the trial for the first time for eachdose;

2) If<2 DLT (dose limit toxicity) symptomatic intracranial hemorrhages occur within 24 hours after EVT, the trial advances to the next dose level;

3) If 2/14 DLT, then include 8 more people at the same dose;

4) If 2/14+0-1/8DLT (9.1% to 13.6%), proceed to the next dose level;

5) If 2/14+2/8 DLT (18.2%) or 3/14 DLT, then this dose is deemed unsafe and the prior lower dose is the MTD.

329

Dose Expansion (Phase IIa):

In Phase IIa randomization will allocate to randomize 46 subjects each into dose group A and dose group B, and 65 subjects into the control group in a 1:1: $\sqrt{2}$ ratio. This approach is similar to the sample size calculation method used in the APRIL study.¹⁸

334 Statistical analyses

Continuous variables will be summarized with the median, the 335 inter-quartile range, the minimum, and the maximum. Categorical 336 variables will be summarized with counts and percentages. Patient 337 compliance with eligibility criteria and treatment administration, major 338 protocol non-compliance, patient withdrawal and the reason for 339 withdrawal (e.g., adverse event, protocol non-compliance, lost to follow 340 up, failed to return, consent withdrawal, and other reasons) and 341 assignment to each analysis population will be summarized using 342 appropriate statistics by treatment arms. 343

The statistical results of outcome analyses will be provided with point estimates of treatment differences with 95% confidence intervals (CIs).

17 / 24

The primary outcome in both phase Ib and IIa will be analyzed using 347 generalized linear models from which a risk ratio with its 95% CI will be 348 estimated as a measurement of treatment effect. The secondary outcomes 349 and safety outcomes (binary, continuous and ordinal) will be analyzed 350 using generalized linear models. For non-normal continuous outcome, a 351 win ratio will be estimated as a measurement of treatment effect. A 352 pooled analysis that combines the phase Ib and phase IIa will be 353 performed as supportive analysis. The primary data analyses will adhere 354 to the intention-to-treat principle. Additionally, per-protocol analyses will 355 be conducted as supplementary analyses. 356

All statistical analyses will be described in detail in the statistical analysis plan which will be finalized before the study database lock, and will be performed using SAS version 9.4 (SAS Institute) and R version 4.4.0 or higher (R Foundation for Statistical Computing). The reporting of trial results will conform to the Consolidated Standards of Reporting Trials guidelines for randomized trials.

363 **Ethical considerations**

The study adheres to the ethical guidelines outlined in the Declaration of Helsinki. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of the Army Medical University and all participating centers. Any modifications to the trial

protocol will only be executed after obtaining further approval from theethics committee.

370 **Discussion**

Despite advancements in thrombectomy devices and workflow 371 processes, outcomes for patients with LVO remain suboptimal. 372 Adjunctive intra-arterial thrombolysis following successful reperfusion in 373 patients with LVO stroke has the potential to improve functional 374 outcomes, while the optimal dose remains unclear. To our knowledge, the 375 DATE trial is the first to evaluate the safety, efficacy, and dose-response 376 effects of intra-arterial tenecteplase in patients with LVO stroke after 377 successful EVT. 378

The CHOICE study demonstrated the potential benefits of intra-arterial alteplase at a dose equivalent to 1/4 of the standard intravenous thrombolytic dose for patients with acute ischemic stroke due to LVO following successful recanalization.⁸ However, it did not conduct a dose escalation exploratory trial, leaving the ideal dose that balances efficacy and safety unknown.

Tenecteplase, a third-generation thrombolytic drug, has demonstrated superiority over alteplase in improving excellent functional outcomes and reducing disability at 3 months.¹⁹ There is an important need to determine which dose provides the best balance of efficacy and safety in patients with LVO following successful EVT. Current trials

such as POST-TNK²⁰ and ANGEL-TNK²¹ are exploring different doses 390 of intra-arterial tenecteplase in patients with acute ischemic stroke due to 391 LVO following successful EVT, using doses of 0.0625 mg/kg, 0.0625 392 mg/kg, and 0.125 mg/kg, respectively. However, the IA doses in these 393 trials were determined based on a similar fraction of the IV alteplase dose 394 used in CHOICE (one fourth) or were based on trial steering committee 395 recommendation, rather than dose-escalation study. Therefore, this study 396 will provide insight to characterize the optimal dose of adjunctive 397 intra-arterial tenectepalse administration in these patients. 398

The DATE trial enrolled its first patient on July 27, 2023, and as of August 25, 2024 has enrolled 205 subjects. Full study completion (including collection on 3-month outcomes) is expected by November 2024. When completed, this trial will provide pivotal data allowing assessment of the optimal dose, safety, and efficacy of intra-arterial tenecteplase in patients with acute ischemic stroke due to LVO following successful EVT.

406 Funding

The project was supported by the Key Project of Chongqing Science (2023ZDXM025), National Natural Science Foundation of China (No. 82425021), and Health Joint Medical Research Project and the Major Project of Clinical Research Incubation at the First Affiliated Hospital of Army Medical University (2023IITZD01).

20 / 24

412 **Conflicts of interest**

The author(s) declare the following potential conflicts of interest 413 with respect to the research, authorship, and/or publication of this article: 414 JLS reports consulting fees for advising on rigorous and safe clinical trial 415 design and conduct from Biogen, Boehringer Ingelheim, Genentech, 416 Johnson & Johnson, Phenox, Phillips, Rapid Medical, and Roche. TNN 417 discloses Associate Editor of Stroke, advisory board of Aruna Bio and, 418 Brainomix. RGN reports consulting fees for advisory roles with 419 Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine, 420 Imperative 421

Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker 422 Neurovascular, Shanghai Wallaby, Synchron, and stock options for 423 advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, 424 Corindus Vascular Robotics, CrestecBio Inc., Euphrates Vascular, Inc., 425 Vesalio, Viz-AI, RapidPulse and Perfuze. RGN is one of the Principal 426 Investigators of ENDOLOW trial. Funding for this project is provided by 427 Cerenovus. RGN is the Principal Investigator of the DUSK trial. Funding 428 for this project is provided by Stryker Neurovascular. RGN is an investor 429 in Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, Tulavi 430 Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis AI, and 431 Viseon. T.Nguyen reports Associate Editor of Stroke; advisory board of 432 Brainomix, Aruna Bio; speaker for Genentech and Kaneka. Other 433

author(s) declare no potential conflicts of interest with respect to theresearch, authorship, and/or publication of I article.

436 **Contributorship:**

ZZ, WZ, XH, DW, JLS, TNN, and RGN designed and
conceptualized the study. XH, JH, CG, YH, LW, LC, QL, JW, and MW
participated in data collection. XH, YH, JH, and CG wrote the manuscript.

All authors critically revised and approved the manuscript.

441 Acknowledgement

442 None.

443 **References**

444	1.	Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic
445		analysis for the Global Burden of Disease Study 2019. The Lancet Neurology.
446		2021;20(10):795-820.
447	2.	Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients
448		With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management
449		of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart
450		Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
451	3.	Goyal M, Menon B, van Zwam W, et al. Endovascular thrombectomy after large-vessel
452		ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
453		Lancet (London, England). 2016;387(10029):1723-1731.
454	4.	Liebeskind DS, Bracard S, Guillemin F, et al. eTICI reperfusion: defining success in
455		endovascular stroke therapy. J Neurointerv Surg. 2019;11(5):433-438.
456	5.	Ng F, Churilov L, Yassi N, et al. Prevalence and Significance of Impaired Microvascular Tissue
457		Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). Neurology.
458		2022;98(8):e790-e801.
459	6.	Laredo C, Rodriguez A, Oleaga L, et al. Adjunct Thrombolysis Enhances Brain Reperfusion
460		following Successful Thrombectomy. Ann Neurol. 2022;92(5):860-870.
461	7.	Jia M, Jin F, Li S, et al. No-reflow after stroke reperfusion therapy: An emerging phenomenon
462		to be explored. CNS neuroscience & therapeutics. 2024;30(2):e14631.
463	8.	Renú A, Millán M, San Román L, et al. Effect of Intra-arterial Alteplase vs Placebo Following
464		Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion
465		Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. Jama. 2022;327(9):826-835.

466	9.	Tsivgoulis G, Katsanos AH, Sandset EC, et al. Thrombolysis for acute ischaemic stroke: current
467	9.	status and future perspectives. The Lancet Neurology. 2023;22(5):418-429.
468	10.	Coutts SB, Berge E, Campbell BC, Muir KW, Parsons MW. Tenecteplase for the treatment of
469	10.	acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
409 470		
470 471		International journal of stroke : official journal of the International Stroke Society.
	11	2018;13(9):885-892.
472 472	11.	Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic
473		
474	10	Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. <i>Jama</i> . 2020;323(13):1257-1265.
475	12.	Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with
476	10	perfusion-imaging selection. <i>N Engl J Med.</i> 2015;372(11):1009-1018.
477	13.	Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance
478		for protocols of clinical trials. <i>BMJ (Clinical research ed).</i> 2013;346:e7586.
479	14.	Zhang X, Xie Y, Wang H, et al. Symptomatic Intracranial Hemorrhage After Mechanical
480		Thrombectomy in Chinese Ischemic Stroke Patients: The ASIAN Score. <i>Stroke</i> .
481	45	2020;51(9):2690-2696.
482	15.	Huang JH, Su QM, Yang J, et al. Sample sizes in dosage investigational clinical trials: a
483	4.5	systematic evaluation. <i>Drug design, development and therapy</i> . 2015;9:305-312.
484	16.	Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and
485		Well-Performing Design for Phase I Oncology Trials. <i>Clinical cancer research : an official</i>
486	. –	journal of the American Association for Cancer Research. 2016;22(17):4291-4301.
487	17.	Wang Y, Han S, Qin H, et al. Chinese Stroke Association guidelines for clinical management of
488		cerebrovascular disorders: executive summary and 2019 update of the management of
489		high-risk population. <i>Stroke and vascular neurology</i> . 2020;5(3):270-278.
490	18.	Hernández-Jiménez M, Abad-Santos F, Cotgreave I, et al. Safety and Efficacy of ApTOLL in
491		Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized
492		Clinical Trial. JAMA neurology. 2023;80(8):779-788.
493	19.	Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke
494		Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Neurology.</i>
495		2024;103(9):e209903.
496	20.	Jiacheng Huang CG, Jie Yang, Xiaolei Shi, Chang Liu, Jiaxing Song, Fengli Li, Weilin Kong, Shitao
497		Fan, Zhouzhou Peng, Shihai Yang, Jinfu Ma, Xu Xu, Linyu Li, Zhixi Wang, Nizhen Yu, Wenzhe
498		Sun, Chengsong Yue, Xiang Liu, Dahong Yang, Cheng Huang, Duolao Wang, Raul G. Nogueira,
499		Thanh N. Nguyen, Jeffrey L. Saver, Yangmei Chen, Wenjie Zi. Adjunctive Intra-arterial
500		Tenecteplase after Successful Endovascular Thrombectomy in Patients with Large Vessel
501		Occlusion Stroke (POST-TNK): Study Rationale and Design. <i>European Stroke Journal.</i> 2024.
502	21.	Huo X, Luo G, Sun D, et al. Intra-arterial tenecteplase after successful endovascular therapy
503		(ANGEL-TNK): protocol of a multicentre, open-label, blinded end-point, prospective,
504		randomised trial. Stroke and vascular neurology. 2024.
505		
500		
506		
507		

Figure 1. Flow chart for the Phase I of the DATE trial. 508

509

